<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413139</url>
  </required_header>
  <id_info>
    <org_study_id>FMRP-100701</org_study_id>
    <nct_id>NCT01413139</nct_id>
  </id_info>
  <brief_title>4-EVER : a Trial Investigating the Safety of 4F Endovascular Treatment of Infra-Inguinal Arterial Stenotic Disease</brief_title>
  <acronym>4-EVER</acronym>
  <official_title>4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flanders Medical Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flanders Medical Research Program</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to evaluate puncture site complication rate&#xD;
      as well as the short- and long-term (up to 24 months) outcome of treatment by means of Astron&#xD;
      Pulsar / Astron Pulsar-18 stent implantation in symptomatic (Rutherford 2-4) femoro-popliteal&#xD;
      arterial stenotic or occlusive lesions, using 4F compatible devices of BIOTRONIK and without&#xD;
      the use of a closure device.&#xD;
&#xD;
      The hypothesis is that the primary patency at 12 months is non-inferior to the primary&#xD;
      patency obtained in the Durability study (72.2%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency at 12 months as indicated by an independently verified duplex ultrasound peak systolic velocity ratio (PSVR) &lt;2.5 in the target vessel with no reintervention</measure>
    <time_frame>12 months</time_frame>
    <description>Primary patency at 12 months, defined as freedom from &gt;50% restenosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>1 day post-procedure</time_frame>
    <description>Technical success, defined as the ability to cross and stent the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puncture site complications</measure>
    <time_frame>10 days</time_frame>
    <description>Number of puncture site complications in the absence of a closure device after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>6- &amp; 24-month follow-up</time_frame>
    <description>Primary patency rate at 6- &amp; 24-month follow-up, defined as freedom from &gt;50% restenosis at 6 &amp; 24 months as indicated by an independently verified duplex ultrasound peak systolic velocity ratio (PSVR) &lt;2.5 in the target vessel with no reintervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>6-, 12- &amp; 24-month follow-up</time_frame>
    <description>Clinical success at follow-up is defined as an improvement of Rutherford classification at 6-, 12- &amp; 24-month follow-up of one class or more as compared to the pre-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture rate at 12- &amp; 24-month follow-up</measure>
    <time_frame>12- &amp; 24-month follow-up</time_frame>
    <description>Stent fracture rate at 12- &amp; 24-month follow-up (in patient who were treated with stentplacement), as determined according the following classification on x-ray:&#xD;
Class 0 : no strut factures&#xD;
Class I : single tine fracture&#xD;
Class II : multiple tine factures&#xD;
Class III : Stent fracture(s) with preserved alignment of the components&#xD;
Class IV : Stent fracture(s) with mal-alignment of the components&#xD;
Class V : Stent fracture(s) in a trans-axial spiral configuration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Claudication</condition>
  <arm_group>
    <arm_group_label>4F portfolio products from Biotronik</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>4F portfolio products from Biotronik</intervention_name>
    <description>4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18</description>
    <arm_group_label>4F portfolio products from Biotronik</arm_group_label>
    <other_name>Astron pulsar</other_name>
    <other_name>Astron Pulsar-18</other_name>
    <other_name>Fortress</other_name>
    <other_name>Passeo-18</other_name>
    <other_name>Cruiser-18</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  De novo, restenotic or reoccluded lesion located in the femoropopliteal arteries&#xD;
             suitable for endovascular treatment&#xD;
&#xD;
          -  Patient presenting with a score from 2 to 4 according to the Rutherford classification&#xD;
&#xD;
          -  Patient is willing to comply with specified follow-up evaluations at the predefined&#xD;
             time intervals times&#xD;
&#xD;
          -  Patient is &gt;18 years old&#xD;
&#xD;
          -  Patient understands the nature of the procedure and provides written informed consent,&#xD;
             prior to enrollment in the study&#xD;
&#xD;
          -  Prior to enrollment, the target lesion was crossed with standard guidewire&#xD;
             manipulation&#xD;
&#xD;
          -  Patient is eligible for treatment with 4F compatible devices&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          -  The target lesions are located within the native superficial femoral artery: Distal&#xD;
             point 3 cm above knee joint and 1 cm below the origin of the profunda femoralis.&#xD;
&#xD;
          -  The target lesion has angiographic evidence of stenosis or restenosis &gt; 50% or&#xD;
             occlusion&#xD;
&#xD;
          -  Length of the target lesion is =20 cm by visual estimation and can be covered with one&#xD;
             stent&#xD;
&#xD;
          -  Target vessel diameter visually estimated is =4 mm and =6.5 mm&#xD;
&#xD;
          -  There is angiographic evidence of at least one-vessel-runoff to the foot&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of another stent in the target vessel that was placed during a previous&#xD;
             procedure&#xD;
&#xD;
          -  Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis&#xD;
&#xD;
          -  Previous bypass surgery in the same limb&#xD;
&#xD;
          -  Patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics&#xD;
&#xD;
          -  Patients who exhibit persistent acute intraluminal thrombus at the target lesion site&#xD;
&#xD;
          -  Perforation at the angioplasty site evidenced by extravasation of contrast medium&#xD;
&#xD;
          -  Patients with known hypersensitivity to nickel-titanium&#xD;
&#xD;
          -  Patients with uncorrected bleeding disorders&#xD;
&#xD;
          -  Female patient with child bearing potential not taking adequate contraceptives or&#xD;
             currently breastfeeding&#xD;
&#xD;
          -  Life expectancy of less than 12 months&#xD;
&#xD;
          -  Ipsilateral iliac artery treatment before target lesion treatment with a residual&#xD;
             stenosis &gt; 30%&#xD;
&#xD;
          -  Use of thrombectomy, atherectomy or laser devices during procedure&#xD;
&#xD;
          -  Any planned surgical intervention/procedure 30 days after the study procedure&#xD;
&#xD;
          -  Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
&#xD;
          -  Patient is currently participating in another investigational drug or device study&#xD;
             that has not reached the primary endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Bosiers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint Blasius, Dendermonde, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imelda hospital</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair ziekenhuis antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermonde</city>
        <state>Oost-Vlaanderen</state>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park-Krankenhaus Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Fransiskus hospital</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral Vascular Disease</keyword>
  <keyword>claudication</keyword>
  <keyword>rest pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

